Peer-Reviewed Publications

    Perceived risks associated with the use of tobacco and nicotine-containing products: Findings from qualitative research

    Salzberger, T.; Chrea, C.; Cano, S.; Martin, M.; Atkison, M.; Emilien, G.; Mainy, N.; Ramazzotti, A.; Weitkunat, R.; Lüdicke, F.

    Published
    Dec 1, 2017
    DOI
    10.16135/j.issn1002-0861.2017.0562
    Link to publication
    Topic
    Summary

    When evaluating the public health effects of novel tobacco products, such as candidate modified risk tobacco products (cMRTPs), risk perceptions are important as they are potential determinants of product use. In this paper, we describe the development of a conceptual framework of perceived risks associated with the use of tobacco and nicotine-containing products. We conducted a literature review, held 12 focus group discussions in the USA, and elicited expert opinions to identify key concepts related to risk perceptions of tobacco and nicotine-containing products. The literature review, focus groups, and expert opinions provided evidence for triangulation, revealing that the key concepts could form the basis of a conceptual framework in 5 domains: perceived health risk to self, perceived health risk to others, perceived addiction risk, perceived social risk, and perceived practical risk. This new framework can be used to support population-based and clinical research, establish the validity of the current research strategies, and develop evidence-based guidance for the development of new self-report instruments that are needed to evaluate the public health effects of novel tobacco products.

    Related Publications

    Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

    Clinical

    Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

    Clinical

    Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

    Clinical

    Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

    Clinical

    Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

    Clinical

    Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

    Clinical

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.